Understanding why ALK-targeted treatment may not work
Part of Cancer, Lungs & breathing clinical trials.
This study looks at why some people with ALK-positive non-small cell lung cancer do not respond to ALK inhibitor drugs. By studying tissue and blood samples, researchers hope to find reasons for resistance and improve future treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have non-small cell lung cancer (a common type of lung cancer).
- Your tumor has a change called an ALK gene fusion (a specific genetic marker).
- You have started treatment with an ALK inhibitor (a targeted therapy drug) but it did not work, or your cancer grew within 3 to 6 months.
- You have not had other cancer treatments besides ALK inhibitors.
- You are willing to provide a tumor biopsy and blood sample, and give written consent.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at why certain EGFR-positive advanced lung cancers resist third-generation EGFR tablet treatment given as the first treatment. Your body samples and scan results help researchers understand the resistance, which may guide better future care.
This trial looks at the genetic changes in non-small cell lung cancer (NSCLC) that has stopped responding to targeted therapy pills. It aims to understand why the cancer became resistant, which may help find better treatments.
This study looks at biological changes in advanced lung cancer that has an ALK rearrangement, using regular blood samples (and sometimes tumor tissue if available). It may help researchers better understand how this cancer behaves and how it responds to first-line ALK-targeted treatment.
This study takes a small tumor sample early after starting targeted treatment (or uses blood if a biopsy isn’t possible) to look for clues—called biomarkers—about why some tumor cells survive. The results may help improve how future patients’ treatments are chosen for certain lung cancer gene mutations.
This study looks at what happens when lung cancer stops responding to the drug lorlatinib, which is used as the first treatment for ALK-positive non-small cell lung cancer. It aims to find out why the drug stops working and what the next best treatment might be, which could help guide future care.
This study uses a computer to analyze digital images of tumor tissue from people with a certain type of lung cancer (ALK-positive non-small cell lung cancer). It aims to see if the computer can predict how well newer-generation ALK inhibitors work in these patients.
Hear when a new NGS trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.